<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of severe malaria</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of severe malaria</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment of severe malaria</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Terrie E Taylor, DO</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Johanna Daily, MD, MSc</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elinor L Baron, MD, DTMH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 18, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Severe malaria is defined as presence of <em>Plasmodium falciparum</em> parasitemia and one or more of the manifestations in the table  (<a class="graphic graphic_table graphicRef107439" href="/d/graphic/107439.html" rel="external">table 1</a>).</p><p>Most cases of severe malaria are attributable to <em>P. falciparum </em>(90 percent), but <em>Plasmodium vivax </em>and <em>Plasmodium knowlesi </em>can also cause severe disease [<a href="#rid1">1-5</a>]. Approximately 627,000 deaths are caused by malaria each year; over 90 percent of the deaths occur among children in sub-Saharan Africa [<a href="#rid2">2</a>].</p><p>Management of patients with severe malaria presents a broad array of clinical challenges given the complex pathophysiology of an infection that involves multiple organ systems. These challenges are increased in endemic areas where access to diagnostic and therapeutic tools may be limited. </p><p>The approach to treatment of severe malaria will be reviewed here. </p><p>Issues related to diagnosis of malaria are discussed further separately. (See  <a class="medical medical_review" href="/d/html/5709.html" rel="external">"Malaria: Clinical manifestations and diagnosis in nonpregnant adults and children", section on 'Severe malaria'</a> and  <a class="medical medical_review" href="/d/html/5707.html" rel="external">"Laboratory tools for diagnosis of malaria"</a>.)</p><p>Issues related to treatment of uncomplicated malaria are discussed separately. (See  <a class="medical medical_review" href="/d/html/5704.html" rel="external">"Treatment of uncomplicated falciparum malaria in nonpregnant adults and children"</a> and  <a class="medical medical_review" href="/d/html/4812.html" rel="external">"Malaria in pregnancy: Prevention and treatment"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">DEFINITION</span><span class="headingEndMark"> — </span>Severe falciparum malaria is defined as one or more of the following in the absence of an identified alternative cause and in the presence of <em>P. falciparum </em>parasitemia [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Impaired consciousness</strong> – Glasgow Coma Score &lt;11 in adults or Blantyre Coma Score &lt;3 in children.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prostration</strong> – Generalized weakness so that a person is unable to sit, stand, or walk without assistance.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Multiple convulsions</strong> – More than two episodes within 24 hours.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acidosis</strong> – A base deficit of &gt;8 mEq/L, or, if not available, a plasma bicarbonate level of &lt;15 mmol/L, or venous plasma lactate ≥5 mmol/L. Clinical indicators of acidosis include rapid, deep, labored breathing.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypoglycemia</strong> – Blood or plasma glucose &lt;40 mg/dL (&lt;2.2 mmol/L).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severe malarial anemia</strong> – Hemoglobin concentration ≤5 g/dL or hematocrit ≤15 percent in children &lt;12 years of age (&lt;7 g/dL and &lt;20 percent, respectively, in adults) with parasite count &gt;10,000/mcL.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Renal impairment</strong> – Plasma or serum creatinine &gt;3 mg/dL (265 mcmol/L) or blood urea &gt;20 mmol/L.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Jaundice </strong>– Plasma or serum bilirubin &gt;50 mcmol/L (3 mg/dL) with a parasite count &gt;100,000/mcL (approximately 2 percent) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pulmonary edema</strong> – Radiographically confirmed or oxygen saturation &lt;92 percent on room air with respiratory rate &gt;30/min, often with chest indrawing and crepitation on auscultation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Significant bleeding</strong> – Including recurrent or prolonged bleeding from the nose, gums, or venipuncture sites, hematemesis, or melena.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Shock </strong>– Compensated shock is defined as capillary refill ≥3 seconds or temperature gradient on leg (mid to proximal limb) but no hypotension. Decompensated shock is defined as systolic blood pressure &lt;70 mmHg in children or &lt;80 mmHg in adults, with evidence of impaired perfusion (cool peripheries or prolonged capillary refill).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>P. falciparum</em></strong><strong> parasitemia</strong> – &gt;10 percent (&gt;500,000/mcL).</p><p></p><p>The definition of severe <em>P. vivax</em> malaria is the same as that of severe falciparum malaria except that there are no <em>P. vivax</em> parasite density thresholds [<a href="#rid1">1</a>]. The definition of severe malaria due to <em>P. knowlesi </em>differs from that of severe falciparum malaria; the threshold parasite density is &gt;100,000/mcL (alone) or &gt;20,000/mcL in patients with jaundice [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/d/html/112633.html" rel="external">"Non-falciparum malaria: Plasmodium knowlesi", section on 'Severe infection'</a>.)</p><p>Administration of empiric treatment for malaria is warranted for patients with the above manifestations while clinical evaluation for alternative causes is pursued.</p><p>Issues related to clinical manifestations of severe malaria are discussed further separately. (See  <a class="medical medical_review" href="/d/html/5709.html" rel="external">"Malaria: Clinical manifestations and diagnosis in nonpregnant adults and children", section on 'Severe malaria'</a>.)</p><p class="headingAnchor" id="H4"><span class="h1">INITIAL MANAGEMENT ISSUES</span></p><p class="headingAnchor" id="H5"><span class="h2">General principles</span><span class="headingEndMark"> — </span>Death due to severe malaria can occur within hours of presentation, so prompt assessment and initiation of antimalarial therapy is essential. Patients should be evaluated with attention to findings consistent with malaria as well as additional and/or alternative causes of presenting symptoms. A full neurologic assessment should be performed, including assessment of the Blantyre Coma Score for children  (<a class="graphic graphic_table graphicRef74361" href="/d/graphic/74361.html" rel="external">table 2</a>); the Glasgow Coma Scale is suitable for adults  (<a class="graphic graphic_table graphicRef81854" href="/d/graphic/81854.html" rel="external">table 3</a>). Temperature, heart rate and rhythm, respiratory rate and rhythm, blood pressure, oxygen saturation, and weight should be noted, as should capillary refill and degree of pallor. (See  <a class="medical medical_review" href="/d/html/5104.html" rel="external">"Stupor and coma in adults"</a> and  <a class="medical medical_review" href="/d/html/6225.html" rel="external">"Evaluation of stupor and coma in children"</a>.)</p><p>Of primary importance in the treatment of malaria is the provision of prompt, effective antimalarial therapy and concurrent supportive care to manage life-threatening complications of the disease. Supportive measures (eg, oxygen, ventilatory support, cardiac monitoring, and pulse oximetry) should be instituted as needed. During this time, intravenous catheters should be placed, and fingerprick blood samples should be obtained for laboratory tests needed immediately. Point-of-care testing machines can be used for rapid determination of hematocrit (packed cell volume or hemoglobin), glucose, and lactate. Additional tests can be done if/when indicated: electrolytes, blood gases, renal function tests, full blood count, type and cross, blood culture, and clotting studies. Unconscious patients should have a lumbar puncture to rule out concomitant bacterial meningitis in the absence of contraindications (eg, clinically stable enough to undergo the procedure, no lateralizing signs) [<a href="#rid6">6</a>]. These tasks should overlap with institution of antimalarial treatment as well as other ancillary therapies as needed (including anticonvulsants, intravenous glucose and fluids, antipyretics, antibiotics, and blood transfusion).</p><p>Repeat clinical assessments should be performed every two to four hours for prompt detection and management of complications (in an intensive care setting, if possible). If the coma score decreases after initiation of treatment, investigations should focus on the possibility of seizures, hypoglycemia, or worsening anemia. Repeat laboratory assessments of parasitemia, hemoglobin/hematocrit, glucose, and lactate should be performed in six-hour intervals. A flowchart summarizing the vital information may be used to guide management decisions  (<a class="graphic graphic_table graphicRef79603" href="/d/graphic/79603.html" rel="external">table 4</a>) [<a href="#rid7">7</a>].</p><p>Important independent predictors for fatality among African children with severe malaria include acidosis, impaired consciousness (coma and/or convulsions), severe acute kidney injury (defined as a &gt;2-fold increase in creatinine over the estimated baseline) [<a href="#rid8">8</a>], and signs of chronic disease (lymphadenopathy, malnutrition, candidiasis, severe visible wasting, and desquamation) [<a href="#rid9">9</a>]. This was illustrated in a large clinical study including 5246 African children with severe malaria. Other factors that were statistically significant predictors of death in univariate analyses but not in the multivariate model included tachypnea, deep breathing, shock, prostration, low pH, hyperparasitemia, severe anemia, and jaundice. Clinical features previously identified as being poor prognostic features that did not correlate with mortality in this study included age, glucose level, axillary temperature, parasite density, and blackwater fever. </p><p>Careful observation and thoughtful responses to changes in clinical status are the most important elements in looking after patients with severe malaria. Patients can make remarkable recoveries, and the time and effort to address the components of clinical care described in the following sections can reap tangible rewards in a relatively short period of time.</p><p class="headingAnchor" id="H6"><span class="h2">Antimalarial therapy</span><span class="headingEndMark"> — </span>The risk of death due to severe malaria is greatest in the first 24 hours after clinical presentation.</p><p>Intravenous therapy should be initiated promptly, with close monitoring of parasite density. There are two major classes of drugs available for parenteral treatment of severe malaria: the artemisinin derivatives (<a class="drug drug_general" data-topicid="17088" href="/d/drug information/17088.html" rel="external">artesunate</a> and artemether) and the cinchona alkaloids (<a class="drug drug_general" data-topicid="9847" href="/d/drug information/9847.html" rel="external">quinine</a> and <a class="drug drug_general" data-topicid="9846" href="/d/drug information/9846.html" rel="external">quinidine</a>) [<a href="#rid1">1</a>].</p><p>Patients who have received parenteral therapy for at least 24 hours and can tolerate oral medication may transition to an oral regimen for completion of therapy.</p><p class="headingAnchor" id="H1003933628"><span class="h3">Prereferral treatment in rural endemic areas</span><span class="headingEndMark"> — </span>In areas where patients with severe malaria cannot begin intravenous therapy immediately and where artemisinin derivatives are readily available, patients should be treated with a prereferral dose of intramuscular or rectal therapy and triaged to an acute care facility.</p><p>A single dose of intramuscular <a class="drug drug_general" data-topicid="17088" href="/d/drug information/17088.html" rel="external">artesunate</a> is preferred [<a href="#rid1">1</a>]. Children weighing less than 20 kg should receive 3 mg/kg/dose. For larger children and adults, the dose is 2.4 mg/kg [<a href="#rid1">1</a>].</p><p>If intramuscular <a class="drug drug_general" data-topicid="17088" href="/d/drug information/17088.html" rel="external">artesunate</a> is not available [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>For individuals ≥6 years, intramuscular artemether (loading dose 3.2 mg/kg) should be used; if this is not available, intramuscular <a class="drug drug_general" data-topicid="9847" href="/d/drug information/9847.html" rel="external">quinine</a> (loading dose 20 mg/kg, divided into two 10 mg/kg injections, one in each anterior thigh to avoid damaging the sciatic nerve) should be used.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For individuals &lt;6 years, rectal <a class="drug drug_general" data-topicid="17088" href="/d/drug information/17088.html" rel="external">artesunate</a> (10 mg/kg) should be used. If rectal artesunate is not available, intramuscular artemether should be used (loading dose 3.2 mg/kg); if this is not available, intramuscular <a class="drug drug_general" data-topicid="9847" href="/d/drug information/9847.html" rel="external">quinine</a> should be used (loading dose 20 mg/kg, divided equally between the anterior thighs).</p><p></p><p>If referral is not possible, intramuscular or rectal treatment should be continued until the patient can tolerate oral medication, at which point the course of therapy may be completed orally. (See <a class="local">'Completing therapy'</a> below.)</p><p>A single <a class="drug drug_general" data-topicid="17088" href="/d/drug information/17088.html" rel="external">artesunate</a> rectal suppository pending transport has been demonstrated to reduce mortality in children &lt;6 years of age. This was illustrated in a randomized trial of over 12,000 patients in rural Bangladesh, Ghana, and Tanzania with suspected severe malaria [<a href="#rid10">10</a>]. Dosing consisted of 100 mg for children 6 months to 6 years of age and 400 mg for patients &gt;6 years. Mortality was significantly lower among those who received prereferral rectal artesunate than among those who received placebo (1.9 versus 3.8 percent, respectively; risk ratio 0.49, 95% CI 0.32-0.77). Rectal artesunate is not advised for older children and adults as it has been associated with increased death in these groups (low-quality evidence) [<a href="#rid1">1,11</a>].</p><p class="headingAnchor" id="H3546525"><span class="h3">Initiating therapy</span></p><p class="headingAnchor" id="H1304974321"><span class="h4">General approach</span><span class="headingEndMark"> — </span>Parenteral <a class="drug drug_general" data-topicid="17088" href="/d/drug information/17088.html" rel="external">artesunate</a> (intravenous or intramuscular) is preferred for treatment of adults and children with severe malaria (including infants, pregnant patients in all trimesters, and lactating patients) [<a href="#rid1">1,12-14</a>]. Dosing is summarized in the table  (<a class="graphic graphic_table graphicRef79194" href="/d/graphic/79194.html" rel="external">table 5</a>) [<a href="#rid1">1,15</a>]. Parenteral therapy should be administered for at least 24 hours and until oral medication can be tolerated. (See <a class="local">'Completing therapy'</a> below.)</p><p><a class="drug drug_general" data-topicid="17088" href="/d/drug information/17088.html" rel="external">Artesunate</a> efficacy and adverse effects are discussed below. (See <a class="local">'Artemisinins'</a> below.) </p><p>If parenteral <a class="drug drug_general" data-topicid="17088" href="/d/drug information/17088.html" rel="external">artesunate</a> is not immediately available, patients should receive interim treatment while parenteral artesunate is obtained [<a href="#rid16">16</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span>In the United States, interim treatment consists of oral therapy (administered with an anti-emetic or via nasogastric tube, if necessary) [<a href="#rid17">17</a>]. The preferred oral agent for interim treatment is <a class="drug drug_general" data-topicid="9066" href="/d/drug information/9066.html" rel="external">artemether-lumefantrine</a> because of its rapid onset of action; alternative oral options include <a class="drug drug_general" data-topicid="8704" href="/d/drug information/8704.html" rel="external">atovaquone-proguanil</a> or <a class="drug drug_general" data-topicid="9602" href="/d/drug information/9602.html" rel="external">mefloquine</a>  (<a class="graphic graphic_table graphicRef108036" href="/d/graphic/108036.html" rel="external">table 6</a>). Other oral antimalarials (such as <a class="drug drug_general" data-topicid="9275" href="/d/drug information/9275.html" rel="external">clindamycin</a>, <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a>) are too slow acting for interim treatment of severe malaria. If an oral antimalarial agent was used for chemoprophylaxis, a different agent should be used for treatment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Outside the United States, interim treatment consists of artemether (IM) or <a class="drug drug_general" data-topicid="9847" href="/d/drug information/9847.html" rel="external">quinine</a> (IM or IV) [<a href="#rid1">1</a>]. Dosing is summarized in the table  (<a class="graphic graphic_table graphicRef79194" href="/d/graphic/79194.html" rel="external">table 5</a>)</p><p></p><p class="headingAnchor" id="H529375183"><span class="h4">Areas with artemisinin resistance</span><span class="headingEndMark"> — </span>Emergence of artemisinin resistance is an important concern. Artemisinin resistance in <em>P. falciparum</em> is prevalent in parts of Cambodia, the Lao People’s Democratic Republic, Myanmar, Thailand, and Vietnam. (See  <a class="medical medical_review" href="/d/html/5704.html" rel="external">"Treatment of uncomplicated falciparum malaria in nonpregnant adults and children", section on 'Artemisinin-resistant malaria'</a>.)</p><p>For treatment of severe malaria in areas with established artemisinin resistance, (eg Southeast Asia), we are in agreement with the World Health Organization, which favors coadministration of parenteral <a class="drug drug_general" data-topicid="17088" href="/d/drug information/17088.html" rel="external">artesunate</a> and parenteral <a class="drug drug_general" data-topicid="9847" href="/d/drug information/9847.html" rel="external">quinine</a> in full doses  (<a class="graphic graphic_table graphicRef79194" href="/d/graphic/79194.html" rel="external">table 5</a>) [<a href="#rid1">1</a>]. The approach to completing therapy is outlined below. (See <a class="local">'Completing therapy'</a> below.)</p><p>However, experience with this approach is limited to case reports and retrospective studies [<a href="#rid18">18,19</a>]; further study is needed. </p><p>After the patient is no longer critically ill, oral antimalarial therapy is used to complete the course of treatment. (See <a class="local">'Completing therapy'</a> below.)</p><p class="headingAnchor" id="H374197005"><span class="h4">Antimalarial agents</span></p><p class="headingAnchor" id="H251323317"><span class="h5">Artemisinins</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General principles</strong> – Artemisinin derivatives clear parasitemia faster than <a class="drug drug_general" data-topicid="9847" href="/d/drug information/9847.html" rel="external">quinine</a> and are associated with lower mortality rates in both adults and children [<a href="#rid12">12,13,20</a>]. Artemisinins are active against a broader life cycle range of blood stage parasites than quinine, and they are active against gametocytes [<a href="#rid21">21,22</a>]. </p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="17088" href="/d/drug information/17088.html" rel="external">Artesunate</a> is the most rapid acting of the artemisinin compounds because of its water solubility [<a href="#rid1">1,21</a>]. Artesunate is the preferred therapy for treatment of severe falciparum malaria in adults and children (in areas where intravenous artesunate of reliable quality is readily available) [<a href="#rid1">1,12-14,20,23</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="17088" href="/d/drug information/17088.html" rel="external">Artesunate</a><strong> efficacy</strong> – In a meta-analysis including eight randomized trials enrolling more than 1600 adults and 5700 children [<a href="#rid13">13</a>], treatment with artesunate significantly reduced the risk of death in adults (risk ratio [RR] 0.61, 95% CI 0.50-0.75) and children (RR 0.76, 95% CI 0.65-0.90). In a retrospective study including more than 100 patients with severe malaria treated with artesunate under a United States Centers for Disease Control and Prevention (CDC) investigational protocol, artesunate was a safe and clinically beneficial alternative to <a class="drug drug_general" data-topicid="9846" href="/d/drug information/9846.html" rel="external">quinidine</a> [<a href="#rid24">24</a>]. (See <a class="local">'Quinine'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="17088" href="/d/drug information/17088.html" rel="external">Artesunate</a><strong> adverse effects</strong> – The most common adverse effects include nausea, vomiting, anorexia, and dizziness; however, in some circumstances, these may be due to attributable malaria rather than drug toxicity. </p><p></p><p class="bulletIndent1">Delayed onset of anemia following treatment with <a class="drug drug_general" data-topicid="17088" href="/d/drug information/17088.html" rel="external">artesunate</a> has been described [<a href="#rid25">25-31</a>]. In one review, anemia occurred 8 to 32 days after completion of artesunate therapy; the mean hemoglobin nadir was 6.2 g/dL, and transfusion was required in some cases [<a href="#rid32">32</a>]. The anemia improved within four to eight weeks following completion of artesunate therapy. Patients treated with intravenous artesunate should be monitored for delayed hemolytic anemia, with repeat hemoglobin testing at 7, 14, and 30 days after treatment [<a href="#rid1">1,33,34</a>].</p><p></p><p class="bulletIndent1">The mechanism of delayed-onset anemia is not fully understood but is associated with increased levels of ring erythrocyte surface antigens (measured by flow cytometry) [<a href="#rid33">33</a>] or by plasma <em>P. falciparum</em> histidine-rich protein-2 (PfHRP2) concentrations (measured by dipstick shortly after parasite clearance) [<a href="#rid35">35</a>]. <a class="drug drug_general" data-topicid="17088" href="/d/drug information/17088.html" rel="external">Artesunate</a> may kill malaria parasites without destroying the red blood cell (RBC), which makes the infected RBCs more deformable than other cells, thereby increasing the apparent number of surviving RBCs following parasitemia relative to the number of RBCs in patients treated with other antimalarial agents [<a href="#rid33">33,36,37</a>]. However, the deformable RBCs have a shorter lifespan than nonparasitized RBCs, which may account for delayed-onset anemia following artesunate treatment. Further data are needed to understand if and how artesunate may affect risk for delayed-onset anemia; in general, patients with malaria should have follow-up surveillance hemoglobin concentration evaluated four weeks following completion of treatment for severe malaria. (See  <a class="medical medical_review" href="/d/html/7104.html" rel="external">"Drug-induced hemolytic anemia", section on 'Other mechanisms'</a>.)</p><p></p><p class="bulletIndent1">There is no convincing evidence of neurotoxic effects in humans due to oral or intravenous artemisinins, although neurotoxicity has been described in animals and attributed to fat-soluble artemisinins more frequently than to <a class="drug drug_general" data-topicid="17088" href="/d/drug information/17088.html" rel="external">artesunate</a> [<a href="#rid38">38</a>]. </p><p></p><p class="headingAnchor" id="H8"><span class="h5">Quinine</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications</strong> – Use of parenteral <a class="drug drug_general" data-topicid="9847" href="/d/drug information/9847.html" rel="external">quinine</a> is warranted for treatment of severe malaria in areas with established artemisinin resistance (eg, Southeast Asia); in such cases, parenteral <a class="drug drug_general" data-topicid="17088" href="/d/drug information/17088.html" rel="external">artesunate</a> and parenteral quinine are coadministered in full doses. Dosing is summarized in the table  (<a class="graphic graphic_table graphicRef79194" href="/d/graphic/79194.html" rel="external">table 5</a>) [<a href="#rid1">1</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Parenteral <a class="drug drug_general" data-topicid="9847" href="/d/drug information/9847.html" rel="external">quinine</a> can cause QTc prolongation and should be administered with electrocardiographic monitoring [<a href="#rid39">39</a>]. The QT interval should be monitored hourly, and the infusion should be stopped if the corrected QT interval becomes prolonged by more than 50 percent of the baseline value. The infusion can be renewed (without a bolus) once the QTc falls to &lt;25 percent above the original value. Such monitoring is not necessary in the setting of quinine administration in patients without cardiac abnormalities. (See  <a class="medical medical_review" href="/d/html/86747.html" rel="external">"Major side effects of class I antiarrhythmic drugs"</a>.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9847" href="/d/drug information/9847.html" rel="external">Quinine</a> can act as a pancreatic secretagogue, leading to hyperinsulinemic hypoglycemia. Other toxic effects include tinnitus, reversible hearing loss, nausea, vomiting, dizziness, and visual disturbances.</p><p></p><p class="bulletIndent1">Caution should be exercised for patients recently treated with <a class="drug drug_general" data-topicid="9602" href="/d/drug information/9602.html" rel="external">mefloquine</a> because of the potential for cardiotoxic drug-drug interactions.</p><p></p><p class="headingAnchor" id="H3546619"><span class="h3">Monitoring parasite density</span><span class="headingEndMark"> — </span>During treatment of severe malaria, parasite density should be monitored every 12 hours during the first two to three days to document declining parasite density and confirm adequate response to therapy [<a href="#rid16">16,40,41</a>]. Thereafter, daily blood smears should be performed until smears are negative or until treatment day 7 (if discharged prior to complete clearance of parasitemia, then negative parasitemia should be documented as an outpatient) [<a href="#rid41">41</a>]. (See  <a class="medical medical_review" href="/d/html/5707.html" rel="external">"Laboratory tools for diagnosis of malaria", section on 'Quantification of parasitemia'</a>.)</p><p>With artemisinin therapy, median parasite clearance times are &lt;72 hours [<a href="#rid42">42,43</a>]; prolonged parasite clearance times have been observed in areas of Southeast Asia. With <a class="drug drug_general" data-topicid="9847" href="/d/drug information/9847.html" rel="external">quinine</a>/<a class="drug drug_general" data-topicid="9846" href="/d/drug information/9846.html" rel="external">quinidine</a> therapy, parasite density may be expected to fall by 90 percent over the first 48 hours [<a href="#rid41">41</a>].</p><p>If parasitemia does not clear as expected, confirm that the correct dose is being administered, and consider the possibility of drug resistance or substandard or counterfeit drugs [<a href="#rid44">44</a>]. Administration of an alternative antimalarial for severe disease could be considered.</p><p class="headingAnchor" id="H10"><span class="h3">Completing therapy</span><span class="headingEndMark"> — </span>For nonimmune patients with parasite density &gt;1 percent (at least four hours after the third dose of parenteral therapy), intravenous therapy should be continued up to 6 more days until parasite density ≤1 percent, after which an oral regimen should be given [<a href="#rid16">16,41</a>]. For patients in endemic areas who have received at least 24 hours of parenteral therapy and are able to tolerate oral medications, treatment may be switched to oral therapy even if parasitemia is above 1 percent [<a href="#rid1">1</a>].</p><p>An oral artemisinin combination therapy (ACT) regimen (three-day course) is preferred; if an oral ACT is not available, an alternative regimen may be used. ACT regimens, alternative regimens, and dosing are summarized in the table  (<a class="graphic graphic_table graphicRef108036" href="/d/graphic/108036.html" rel="external">table 6</a>). Data on efficacy of oral regimens for treatment completion are discussed separately. (See  <a class="medical medical_review" href="/d/html/5704.html" rel="external">"Treatment of uncomplicated falciparum malaria in nonpregnant adults and children", section on 'Antimalarial selection'</a>.)</p><p>Patients treated with intravenous <a class="drug drug_general" data-topicid="17088" href="/d/drug information/17088.html" rel="external">artesunate</a> should be monitored for delayed hemolytic anemia, with repeat hemoglobin testing at 7, 14, and 30 days after treatment [<a href="#rid1">1,33,34</a>].</p><p>Regimens containing <a class="drug drug_general" data-topicid="9602" href="/d/drug information/9602.html" rel="external">mefloquine</a> should be avoided for completing therapy in patients who presented with altered consciousness, since there is an increased incidence of neuropsychiatric toxic effects associated with mefloquine in the setting of cerebral malaria [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H2736654768"><span class="h3">Role of postdischarge prophylaxis</span><span class="headingEndMark"> — </span>Administration of postdischarge malaria prophylaxis may be a useful tool for reducing morbidity and mortality among children &lt;5 years of age hospitalized for severe anemia in areas of Africa where malaria is endemic. However, further study is needed to inform the optimal timing, dose, duration, and potential synergism of prophylaxis with other preventive tools (such as vaccines, bed nets, and iron and/or folate supplementation).</p><p>In a randomized trial including 1049 children &lt;5 years of age in Kenya and Uganda hospitalized with severe anemia (hemoglobin &lt;5 g/dL), 85 percent had confirmed malaria infection or were treated for presumed malarial infection [<a href="#rid45">45</a>]. The children received <a class="drug drug_general" data-topicid="9066" href="/d/drug information/9066.html" rel="external">artemether-lumefantrine</a> (three-day course) at discharge and then were randomly assigned to receive placebo or prophylaxis with dihydroartemisinin-piperaquine (administered as three-day courses at 2, 6, and 10 weeks postdischarge). During the intervention period (weeks 3 to 14), the rate of death or readmission was lower among those who received prophylaxis (death rate 2.2 versus 3 percent [hazard ratio 0.74, 95% CI 0.35-1.56]; readmission rate 34 versus 58 percent [hazard ratio 0.63, 95% CI 0.52-0.77]). However, these outcomes were not sustained through 26-week follow up. No serious adverse events were attributed to dihydroartemisinin-piperaquine. </p><p>Issues related to malaria chemoprevention in areas of Africa with seasonal transmission are discussed separately. (See  <a class="medical medical_review" href="/d/html/5702.html" rel="external">"Malaria: Epidemiology, prevention, and control", section on 'Children in areas with perennial transmission'</a>.) </p><p class="headingAnchor" id="H2298178365"><span class="h3">Reducing transmissibility</span><span class="headingEndMark"> — </span>In endemic areas with low transmission, a single dose of oral <a class="drug drug_general" data-topicid="9810" href="/d/drug information/9810.html" rel="external">primaquine</a>, targeting intravascular gametocytes, should be administered to reduce transmissibility of treated <em>P. falciparum</em> infection. This precaution is not necessary in areas in which malaria is not endemic, and it is not cost-effective in moderate-to-high transmission settings. (See  <a class="medical medical_review" href="/d/html/5704.html" rel="external">"Treatment of uncomplicated falciparum malaria in nonpregnant adults and children", section on 'Reducing transmissibility'</a>.)</p><p class="headingAnchor" id="H3217217961"><span class="h2">Pregnancy</span><span class="headingEndMark"> — </span>Pregnant women are more likely to develop severe <em>P. falciparum</em> malaria than other adults, particularly in the second and third trimesters. Complications such as hypoglycemia and pulmonary edema are more common than in nonpregnant individuals. Maternal mortality can approach 50 percent, and fetal death and premature labor are common.</p><p>Prompt antimalarial therapy and supportive care should be administered as outlined in the preceding sections. Parenteral <a class="drug drug_general" data-topicid="17088" href="/d/drug information/17088.html" rel="external">artesunate</a> is the treatment of choice in all trimesters [<a href="#rid1">1</a>]. Among the alternative agents, artemether is preferred over <a class="drug drug_general" data-topicid="9847" href="/d/drug information/9847.html" rel="external">quinine</a> since quinine is associated with recurrent hypoglycemia [<a href="#rid1">1</a>].</p><p>Following administration of parenteral therapy (for at least 24 hours and until oral medication can be tolerated), an oral regimen should be administered. Artemisinin combination therapy (ACT) is preferred; if an oral ACT is not available, an alternative regimen may be used. Regimens and dosing are summarized in the table  (<a class="graphic graphic_table graphicRef52058" href="/d/graphic/52058.html" rel="external">table 7</a>).</p><p>Other issues related to malaria and pregnancy are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/4812.html" rel="external">"Malaria in pregnancy: Prevention and treatment"</a>.)</p><p class="headingAnchor" id="H3132029026"><span class="h1">OTHER ASPECTS OF MANAGEMENT</span></p><p class="headingAnchor" id="H11"><span class="h2">Respiratory status</span><span class="headingEndMark"> — </span>Hypoxemia and rales are not common in the setting of severe malaria; the presence of either should raise suspicion for a concomitant lower respiratory tract infection [<a href="#rid46">46</a>].</p><p>Pulmonary edema may develop, particularly in the settings of renal impairment or severe malarial anemia. Acute respiratory distress syndrome can also complicate severe malaria. The approach to ventilatory management ranges from supplemental oxygen to mechanical ventilation with positive end expiratory pressure. (See  <a class="medical medical_review" href="/d/html/1653.html" rel="external">"Acute respiratory distress syndrome: Ventilator management strategies for adults"</a>.)</p><p>Deep breathing (Kussmaul respirations) is a clinical indicator of metabolic acidosis and is associated with a worse outcome in patients with falciparum malaria [<a href="#rid47">47</a>]. Often, deep breathing is associated with hyperlactatemia, although a study of 3248 Tanzanian children noted that, among the 164 deaths, 45 children with admission blood lactate concentrations &gt;5 mmol/L had no evidence of deep breathing/respiratory compensation [<a href="#rid48">48</a>]. This same study confirmed previous findings of the prognostic significance of hyperlactatemia; that association was even more pronounced in children with severe nonmalarial illness.</p><p class="headingAnchor" id="H12"><span class="h2">Neurologic status</span><span class="headingEndMark"> — </span>The clinical case definition of cerebral malaria includes the following criteria [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Blantyre Coma Score ≤2  (<a class="graphic graphic_table graphicRef74361" href="/d/graphic/74361.html" rel="external">table 2</a>)</p><p class="bulletIndent1"><span class="glyph">●</span><em>P. falciparum</em> parasitemia (any density)</p><p class="bulletIndent1"><span class="glyph">●</span>No other identifiable cause of coma (eg, hypoglycemia, meningitis, or a postictal state) [<a href="#rid1">1</a>]</p><p></p><p>The histologic hallmark of cerebral malaria is cerebral sequestration of parasitized erythrocytes. Autopsy-based studies have demonstrated that cerebral malaria may be incorrectly diagnosed (based on the clinical case definition) in about 25 percent of cases [<a href="#rid49">49,50</a>].</p><p>The most reliable clinical indicator for cerebral malaria in patients who meet the above clinical case definition is the presence of one or more elements of malaria retinopathy: white-centered hemorrhages  (<a class="graphic graphic_picture graphicRef65241" href="/d/graphic/65241.html" rel="external">picture 1A</a>), vessel changes  (<a class="graphic graphic_picture graphicRef64492" href="/d/graphic/64492.html" rel="external">picture 1B</a>), and whitening in areas of the retina  (<a class="graphic graphic_picture graphicRef50690" href="/d/graphic/50690.html" rel="external">picture 1C</a>) [<a href="#rid51">51-53</a>]. These manifestations are associated with severe malaria caused by <em>P. falciparum </em>but do not appear to be a major component of severe malaria caused by <em>P. knowlesi </em>[<a href="#rid54">54</a>].</p><p>Establishing whether retinopathy is present is an important marker for cerebral malaria. In the absence of this finding, alternative causes for coma (such as bacterial infection) should be pursued and treated, even in the presence of established malaria infection. (See <a class="local">'Bacterial infection'</a> below.)</p><p>In children with cerebral malaria, factors highly associated with mortality include increased brain volume (on magnetic resonance imaging) and associated elevated intracranial pressure [<a href="#rid55">55</a>]. The etiology of increased brain volume remains poorly understood and optimal treatments have yet to be identified. In these patients, herniation is a common cause of death.</p><p>Issues related to cerebral malaria are discussed further separately. (See  <a class="medical medical_review" href="/d/html/5709.html" rel="external">"Malaria: Clinical manifestations and diagnosis in nonpregnant adults and children", section on 'Cerebral malaria'</a>.)</p><p class="headingAnchor" id="H13"><span class="h3">Clinical evaluation</span><span class="headingEndMark"> — </span>Clinical evaluation includes full physical exam, a complete neurologic examination, determination of Blantyre Coma Score, and funduscopic evaluation. Patients with altered sensorium should undergo lumbar puncture (in the absence of contraindications, eg clinically stable enough to undergo the procedure with no lateralizing signs) [<a href="#rid6">6</a>]) to exclude concomitant bacterial meningitis [<a href="#rid1">1</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Blantyre Coma Score</strong> – The Blantyre Coma Score is a clinical indicator of severity in children with altered consciousness due to malaria [<a href="#rid56">56</a>]. It was developed based on modifications of Glasgow Coma Score because some key Glasgow indicators are not appropriate for evaluation of altered consciousness in pediatric malaria. Examples include eye opening in response to pain (open-eyed children can be in coma) and verbal response to pain (many children with severe malaria are not yet able to speak) [<a href="#rid57">57</a>].</p><p></p><p class="bulletIndent1">The Blantyre Coma Score is outlined in the table  (<a class="graphic graphic_table graphicRef74361" href="/d/graphic/74361.html" rel="external">table 2</a>). Fully conscious children score 5; Blantyre Coma Score ≤2 is associated with high risk of mortality [<a href="#rid57">57</a>]. Among 2030 children admitted to a pediatric ward in Malawi with Blantyre Coma Score ≤2, the mortality in children with a score of 0, 1, or 2 on admission was 34.2, 16.7, and 10.4 percent, respectively. Patients meeting the standard clinical case definition of cerebral malaria had overall mortality of 17.8 percent. (See <a class="local">'Neurologic status'</a> above.)</p><p></p><p class="bulletIndent1">The Blantyre Coma Score should be reassessed at regular intervals following initiation of therapy. A decrease should prompt re-evaluation for seizures (including consideration of unwitnessed or subclinical events), anemia, and hypoglycemia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Funduscopic exam</strong> – Malarial retinopathy is pathognomonic for cerebral malaria in patients who satisfy the standard clinical case definition [<a href="#rid58">58</a>]. The optic fundi should be evaluated following instillation of mydriatics for pupillary dilatation. Examination should be performed via direct ophthalmoscope (which provides magnification) and indirect ophthalmoscope (which provides three-dimensional perspective and wide field of view). Features of malarial retinopathy include white-centered hemorrhages, vessel changes, and whitened areas of the retina  (<a class="graphic graphic_picture graphicRef65241 graphicRef64492 graphicRef50690" href="/d/graphic/65241.html" rel="external">picture 1A-C</a>) [<a href="#rid51">51</a>].</p><p></p><p class="bulletIndent1">Measurement of plasma pHRP2 concentration may be a useful marker for the presence of retinopathy in areas with high endemicity [<a href="#rid59">59-61</a>]; use of this tool could reduce the need for funduscopic examination, which can be difficult to perform. In a series of 64 children in Malawi with cerebral malaria (defined by presence of retinopathy or histologic evidence of sequestration at autopsy), the sensitivity and specificity of a plasma pHRP2 level of &gt;1700 ng/mL were 98 and 94 percent, respectively [<a href="#rid59">59</a>]. Thus far, pHRP2 is detectable only via enzyme-linked immunosorbent assay, which may not be practical in endemic areas.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lumbar puncture (LP) </strong>– Patients with altered sensorium should undergo LP (in the absence of contraindications, eg clinically stable enough to undergo the procedure in the absence of lateralizing signs) [<a href="#rid6">6</a>] to exclude concomitant bacterial meningitis. In one study including 1075 comatose children with suspected cerebral malaria (of whom 80 percent underwent LP), undergoing LP did not influence the mortality risk [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1">If an LP is not performed, presumptive antibiotic therapy for bacterial meningitis should be initiated. (See  <a class="medical medical_review" href="/d/html/6325.html" rel="external">"Lumbar puncture in children"</a> and  <a class="medical medical_review" href="/d/html/4832.html" rel="external">"Lumbar puncture: Technique, contraindications, and complications in adults"</a>.)</p><p></p><p class="bulletIndent1">In patients with cerebral malaria, the mean opening pressure is about 16 cmH<sub>2</sub>O. Laboratory examination may be normal or may demonstrate slightly elevated total protein level and cell count. In a study comparing cerebrospinal fluid (CSF) findings from 12 children with cerebral malaria and 14 children with presumed viral encephalitis, patients with cerebral malaria had lower white cell count, glucose, and protein levels [<a href="#rid62">62</a>]. Children with malaria had a mean white cell count of 0 cells/mcL (range 0 to 4 cells/mcL); children with viral encephalitis had a mean white cell count of 4 cells/microL (range 0 to 9 cells/mcL). A CSF glucose concentration below 3.4 mmol/L (61 mg/dL) was the best discriminator of cerebral malaria from presumed viral encephalitis.</p><p></p><p class="headingAnchor" id="H14"><span class="h3">Seizure management</span><span class="headingEndMark"> — </span>Seizures occur in up to 70 percent of children with severe malaria; subclinical seizures occur in 15 to 20 percent of cases [<a href="#rid58">58,63</a>]. In an African study comparing 132 pediatric survivors of retinopathy-positive cerebral malaria with age-matched controls, epilepsy, or other neurobehavioral sequelae were observed in nearly one-third of patients [<a href="#rid58">58</a>]. These observations suggest that enhanced seizure control may improve long-term outcomes.</p><p>Seizures may be generalized or focal, and the clinical signs may be subtle (nystagmus, irregular respirations, hypoventilation, or a drop in the Blantyre Coma Score). It is also important to evaluate for causes of seizure besides cerebral malaria (eg, hypoglycemia, fever) and to treat accordingly as outlined in the following sections.</p><p>Benzodiazepines are useful first-line agents for seizure treatment. <a class="drug drug_general" data-topicid="9345" href="/d/drug information/9345.html" rel="external">Diazepam</a> (0.4 mg/kg) can be administered intravenously (IV) or per rectum; <a class="drug drug_general" data-topicid="9573" href="/d/drug information/9573.html" rel="external">lorazepam</a> (0.1 mg/kg) can be administered IV or intraosseously. These doses can be repeated once if seizures do not cease within five minutes of the initial dose. Benzodiazepines should not be combined due to risk of respiratory depression. Intramuscular <a class="drug drug_general" data-topicid="83875" href="/d/drug information/83875.html" rel="external">paraldehyde</a> (2 mg/kg) is another option, especially when respiratory depression is a concern [<a href="#rid1">1</a>].</p><p>If seizures are not controllable with benzodiazepines or <a class="drug drug_general" data-topicid="83875" href="/d/drug information/83875.html" rel="external">paraldehyde</a>, other options in endemic areas include phenobarbitone (<a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">phenobarbital</a> 15 to 20 mg/kg, slow IV push) or <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a> (18 mg/kg diluted in 100 mL normal <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a>, infused over 20 minutes). A 20 mg/kg dose of phenobarbital should not be administered without respiratory support [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/d/html/6192.html" rel="external">"Management of convulsive status epilepticus in children"</a>.)</p><p>If seizures recur, repeat single doses of benzodiazepine may be administered. Alternatively, in resource-limited settings, maintenance doses of <a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">phenobarbital</a> (5 to 15 mg/kg/day, administered orally, via nasogastric tube, or via slow IV push in divided doses every 12 hours) or <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a> (10 mg/kg/day IV in divided doses every 12 hours) may be initiated. Additional seizure management should consist of antiepileptics as discussed separately. (See  <a class="medical medical_review" href="/d/html/6192.html" rel="external">"Management of convulsive status epilepticus in children"</a>.)</p><p>Routine seizure prophylaxis should not be administered in the absence of clinical seizure activity. In one study of 340 children with cerebral malaria randomized to receive <a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">phenobarbital</a> (20 mg/kg) or placebo upon admission to hospital, the mortality among those treated with phenobarbital was significantly higher than that of the placebo group (18 versus 8 percent) [<a href="#rid64">64</a>].</p><p class="headingAnchor" id="H15"><span class="h2">Anemia and coagulopathy</span><span class="headingEndMark"> — </span>Removal of infected and uninfected erythrocytes from the circulation is associated with rapid development of anemia. Patients with severe anemia may present with or without altered consciousness; in addition, severe anemia has been associated with long-term neurocognitive impairment [<a href="#rid65">65</a>]. In endemic areas, hemoglobin concentration may decrease gradually over the course of repeated malaria infections, so patients can be fully alert with hemoglobin concentrations of 2 to 3 g/dL (hematocrit &lt;10 percent). Evaluation for pallor of the conjunctivae, nail beds, and palms can provide a rough estimate of the degree of anemia, since blood vessels in these areas are close to the surface  (<a class="graphic graphic_picture graphicRef70130" href="/d/graphic/70130.html" rel="external">picture 2</a>). (See  <a class="medical medical_review" href="/d/html/7112.html" rel="external">"Anemia in malaria"</a>.)</p><p>Hemoglobin concentration and hematocrit are routinely measured components of complete blood counts, but this may not be available in resource-limited settings or the results may not be available in a timely manner. In such circumstances, the hematocrit can be measured on a fingerprick sample of blood collected into a heparinized capillary tube and centrifuged using a mechanical device  (<a class="graphic graphic_picture graphicRef61513" href="/d/graphic/61513.html" rel="external">picture 3</a>). Alternatively, the hemoglobin concentration can be determined from fingerprick samples of blood collected into cuvettes. This method is more expensive than "spinning a hematocrit" but can be performed readily near the bedside.</p><p>Issues related to iron deficiency and iron supplementation are discussed separately. (See  <a class="medical medical_review" href="/d/html/7112.html" rel="external">"Anemia in malaria", section on 'Management'</a>.)</p><p class="headingAnchor" id="H16"><span class="h3">Transfusion</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Children in endemic areas</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Transfusion risk</strong> – In endemic areas, blood products may be in short supply and associated with increased risk for transmission of infectious diseases. While most blood banks in endemic areas screen for HIV, hepatitis B, and syphilis, such screening may miss donors with HIV infection who have not yet mounted a detectable serologic response to the infection. For these reasons, transfusion should be reserved for patients with poor prognosis. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Indications and approach</strong> – In general, our approach to transfusion is guided by individual clinical circumstances; it is influenced by the World Health Organization (WHO) guidelines as well as the approach outlined by the TRACT trial: </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>WHO</strong> − Transfusion thresholds outlined by the WHO in 2022 (based on expert opinion) for high-transmission and low-transmission settings consist of hemoglobin &lt;5 g/dL and hemoglobin &lt;7 g/dL, respectively [<a href="#rid1">1</a>]. The approach consists of 20 to 30 mL/kg of whole blood (10 to 15 mL/kg of packed red blood cells). This approach may also be guided by other factors including level of consciousness and blood lactate levels. </p><p></p><p class="bulletIndent3">A secondary analysis of an observational study evaluated the impact of transfusion on in-hospital mortality among more than 25,000 children with falciparum malaria in sub-Saharan Africa (The Gambia, Malawi, Gabon, Kenya, and Ghana); transfusion practices were not standardized across sites [<a href="#rid66">66</a>]. In children with normal level of consciousness, the transfusion threshold was 5.8 g/dL; in those with lowered level of consciousness, the transfusion threshold was 10.5 g/dL. Transfusion thresholds for blood lactate concentration levels of &lt;3 mmol/L or 3 to 5 mmol/L were 4.2 g/dL or 6.6 g/dL, respectively; for lactate &gt;5 mmol/L, transfusion was considered irrespective of the hemoglobin concentration.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>TRACT</strong> − A 2021 publication by the TRACT (Transfusion and Treatment of severe anemia in African Children) investigators and other stakeholders proposed an algorithm for approach to transfusion for African children with severe anemia [<a href="#rid67">67</a>]. This algorithm defines severe anemia as Hb &lt;6 g/dL and outlines clinical signs for identification of severe complicated anemia; these include increased work of breathing, altered level of consciousness, dark urine (hemoglobinuria). Indications for transfusion include presence of clinical signs of severe complicated anemia or hemoglobin &lt;4 g/dL. The transfusion volume is guided by axillary temperature [those with fever (temperature&gt;37.5°C) receive 20 mL/kg whole blood (10 mL/kg packed red cells), and those with no fever receive 30 mL/kg whole blood (15 mL/kg packed red cells).</p><p></p><p class="bulletIndent3">The above approach is supported by a randomized trial including more than 1500 Ugandan and Malawian children age 2 months to 12 years of age with uncomplicated severe malaria in which patients were randomly assigned to immediate transfusion (with 20 mL/kg or 30 mL/kg of whole blood) or control (no immediate transfusion; transfusion with 20 mL/kg was triggered by new signs of clinical severity or a drop in hemoglobin to &lt;4 g/dL) [<a href="#rid68">68</a>]. Transfusion was performed for all patients in the immediate group and 49 percent of patients in the control group (median time to transfusion, 1.3 hours vs. 24.9 hours after randomization). No differences in clinical outcome between the groups were observed over 6 months. The triggered-transfusion strategy in the control group resulted in less blood use; however, the length of hospital stay was longer. In addition, no difference in mortality was observed between those who received 20 mL/kg or 30 mL/kg whole blood [<a href="#rid69">69</a>].</p><p></p><p class="bulletIndent2">Monitoring of hemoglobin concentration should continue until parasitemia clears; repeat transfusion may be warranted in some cases. In the setting of severe malaria blood transfusions are generally well tolerated; diuretics are rarely needed since patients are relatively hypovolemic. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Children outside endemic areas </strong>– The approach to transfusion for children outside endemic areas is as described separately; hemoglobin monitoring should continue until the peripheral parasitemia clears. (See  <a class="medical medical_review" href="/d/html/5910.html" rel="external">"Red blood cell transfusion in infants and children: Indications"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adults</strong> – The approach to transfusion for adults within and outside endemic areas is as described separately; hemoglobin monitoring should continue until the peripheral parasitemia clears. (See  <a class="medical medical_review" href="/d/html/7948.html" rel="external">"Indications and hemoglobin thresholds for RBC transfusion in adults"</a>.)</p><p></p><p class="headingAnchor" id="H14102011"><span class="h3">Exchange transfusion</span><span class="headingEndMark"> — </span>Exchange transfusion has been proposed as a means of removing infected red blood cells from the circulation, thereby lowering the parasite burden and replacing with unparasitized cells. There is no role for routine exchange transfusion as there is no evidence supporting its efficacy as adjunctive therapy in severe malaria, and there is no consensus on the indications, approach, benefits, or risks of this procedure [<a href="#rid1">1,70,71</a>].</p><p>The WHO guidelines indicate that it is not possible to make any recommendations regarding the use of exchange transfusion based on the available evidence [<a href="#rid1">1</a>]. The United States Centers for Disease Control and Prevention (CDC) no longer recommends exchange transfusion for treatment of severe malaria [<a href="#rid72">72</a>], based on a review that demonstrated no differences in outcome among patients who underwent exchange transfusion [<a href="#rid71">71</a>]; previously, the CDC recommended exchange transfusion for patients with parasite density &gt;10 percent and end-organ complications [<a href="#rid73">73</a>].</p><p>The American Society for Apheresis supports exchange transfusion as an adjunctive therapy for patients with severe malaria [<a href="#rid74">74</a>], although its consideration of adverse events associated with exchange transfusion for malaria is limited.</p><p class="headingAnchor" id="H17"><span class="h3">Coagulopathy</span><span class="headingEndMark"> — </span>Clinically evident disseminated intravascular coagulation (DIC) in the setting of severe malaria is rare (&lt;5 percent), but profound thrombocytopenia is common, and the microcirculation in many organs is occluded by fibrin thrombi [<a href="#rid49">49</a>]. The approach to DIC is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/1306.html" rel="external">"Evaluation and management of disseminated intravascular coagulation (DIC) in adults"</a> and  <a class="medical medical_review" href="/d/html/5915.html" rel="external">"Disseminated intravascular coagulation in infants and children"</a>.)</p><p class="headingAnchor" id="H3779662679"><span class="h2">Acute kidney injury</span><span class="headingEndMark"> — </span>Renal dysfunction is increasingly recognized as a feature of complicated malaria in adults and children; it is an independent predictor of a poor outcome [<a href="#rid8">8,9</a>]. Elevated concentrations of extracellular hemoglobin in the setting of intravascular hemolysis may be associated with oxidative renal tubular damage.</p><p>Use of adjunctive <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a> in adults with moderate or severe malaria may be renoprotective. In a randomized trial including 62 adults in Southeast Asia with moderate or severe malaria treated with acetaminophen (1 g by enterally every 6 hours for 72 hours) or no acetaminophen, use of acetaminophen was associated with reduction in creatinine (median 23 versus 14 percent), particularly in the setting of prominent intravascular hemolysis (median 37 versus 14 percent) [<a href="#rid75">75</a>].</p><p class="headingAnchor" id="H18"><span class="h2">Fluids and nutrition</span></p><p class="headingAnchor" id="H19"><span class="h3">Hypoglycemia</span><span class="headingEndMark"> — </span>Hypoglycemia is a common complication of malaria and a marker of severe disease; it should be suspected in any patient who is comatose or who deteriorates suddenly [<a href="#rid76">76,77</a>].</p><p>Hypoglycemia is defined as<em> </em>glucose &lt;2.2 mmol/L; the thresholds for intervention are [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Children &lt;5 years: glucose &lt;3 mmol/L (&lt;54 mg/dL)</p><p class="bulletIndent1"><span class="glyph">●</span>Children ≥5 years and adults: glucose &lt;2.2 mmol/L (&lt;40 mg/dL)</p><p></p><p>Clinical manifestations of hypoglycemia include seizure and altered consciousness, although these are not reliable clinical indicators, and blood glucose concentration should be assessed as part of routine evaluation. In resource-limited settings, this may be performed via fingerprick samples of whole blood on indicator strips (with or without handheld glucometers).</p><p>Hypoglycemic patients should have intravenous access established promptly, followed by administration of initial bolus of dextrose (0.25 g/kg of body weight), which is usually achieved with 2.5 mL/kg of 10 percent dextrose solution, since extravasation of higher concentrations of glucose can cause severe tissue damage. Blood glucose measurement after 15 minutes should be repeated, with administration of repeat boluses until the patient is normoglycemic. If glucose measurement is not possible, comatose patients with parasitemia at the time of initial assessment should receive a bolus of 2.5 mL/kg of 10 percent dextrose solution. (See  <a class="medical medical_review" href="/d/html/5805.html" rel="external">"Approach to hypoglycemia in infants and children"</a>.)</p><p>Maintenance intravenous fluids should contain at least 5 percent dextrose; patients with recurrent hypoglycemia should receive 10 percent dextrose (10 percent dextrose can be prepared quickly by withdrawing 100 mL from a 1 liter bag of a 5 percent dextrose solution and replacing it with 100 mL of a 50 percent dextrose solution).</p><p>Patients presenting with normoglycemia can develop hypoglycemia during the course of treatment. In addition, those managed promptly for hypoglycemia at presentation can have subsequent recurrent hypoglycemia. Therefore, blood glucose should be monitored closely during the course of illness with prompt management as outlined above.</p><p>Low blood glucose is associated with a worse prognosis. In a prospective study of 437 children in Mali with presumed severe malaria (85 percent of whom had microscopic evidence of <em>P. falciparum </em>infection), a significant difference in admission glucose concentration was observed between those who died and those who survived (median 4.6 versus 7.6 mmol/L, p&lt;0.001) [<a href="#rid78">78</a>]. Children with initial blood glucose concentrations &lt;2.2 mmol/L were classified as hypoglycemic, those between 2.2 and 4.4 mmol/L were classified as low glycemia, those between 4.4 and 8.3 mmol/L were categorized as normoglycemia, and those with concentrations &gt;8.3 mmol/L were classified as hyperglycemia. The case-fatality rates for hypoglycemia, low glycemia, normal glycemia, and hyperglycemia were 61, 46, 13, and 7 percent, respectively. The adjusted odds ratio was 0.75 (0.64 to 0.88) for case fatality for each 1 mmol/L increase in admission blood glucose concentration, suggesting that the traditional cutoff of 2.2 mmol/L may be too low for adequate sensitivity in the setting of pediatric cerebral malaria.</p><p>The pathogenesis of hypoglycemia in malaria is not fully understood; it may be related to parasite glucose consumption and/or impaired host gluconeogenesis [<a href="#rid77">77</a>]. Malnutrition, adrenal insufficiency, and hyperinsulinemia are not likely causes of hypoglycemia [<a href="#rid77">77</a>]. In addition to primary hypoglycemia, administration of <a class="drug drug_general" data-topicid="9847" href="/d/drug information/9847.html" rel="external">quinine</a> or <a class="drug drug_general" data-topicid="9846" href="/d/drug information/9846.html" rel="external">quinidine</a> (insulin secretagogues) can cause iatrogenic hypoglycemia [<a href="#rid79">79,80</a>]. Hypoglycemia with <a class="drug drug_general" data-topicid="17088" href="/d/drug information/17088.html" rel="external">artesunate</a> therapy is less common than with quinine or quinidine [<a href="#rid12">12</a>].</p><p class="headingAnchor" id="H20"><span class="h3">Volume management</span><span class="headingEndMark"> — </span>The intravascular volume status in the setting of severe malaria is uncertain; there are data to both support and refute the presence of hypovolemia in the setting of severe malaria infection [<a href="#rid81">81,82</a>]. </p><p>Adults with malaria appear to be more vulnerable to fluid overload than children; there is a thin line between underhydration (and thus worsening renal impairment) and overhydration (and risking pulmonary and cerebral edema) [<a href="#rid83">83</a>]. Therefore, fluid requirements should be assessed on an individual basis. </p><p>Reliable markers of intravascular volume depletion in patients with severe malaria include cool peripheries, delayed capillary refill, low venous pressure, and low urine output. Deep breathing (reflecting lactic acidosis) may also be a reasonable indicator of hypovolemia.</p><p>Clinical symptoms of hypovolemia frequently resolve with blood transfusion (when warranted). When transfusion is not indicated, data suggest that repeated boluses of normal <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> or albumin may be counterproductive [<a href="#rid84">84</a>]. In an observational study among 154 adults with severe malaria, restrictive fluid management (2 to 3 mL/kg per hour of crystalloid for the first 24 hours) did not worsen kidney function, tissue perfusion, or blood pressure; development of pulmonary edema was not related to the volume of fluid administration [<a href="#rid85">85</a>]. </p><p>Some data suggest that volume resuscitation with crystalloid is favorable over colloid, although it is uncertain whether crystalloid increases risk of exacerbating cerebral edema in the setting of a fragile blood-brain barrier [<a href="#rid86">86,87</a>]. In resource-challenged settings, crystalloids are generally more readily available and are widely used. </p><p>In the setting of acute renal failure, institution of renal replacement therapy is appropriate if feasible. Hemofiltration is associated with lower mortality than peritoneal dialysis [<a href="#rid88">88</a>]; there have been no comparative trials of hemofiltration and hemodialysis. (See  <a class="medical medical_review" href="/d/html/1927.html" rel="external">"Kidney replacement therapy (dialysis) in acute kidney injury in adults: Indications, timing, and dialysis dose"</a>.)</p><p>Issues related to fluid resuscitation for children with sepsis in resource-limited settings are summarized in the algorithm  (<a class="graphic graphic_algorithm graphicRef143298" href="/d/graphic/143298.html" rel="external">algorithm 1</a>) and discussed separately. (See  <a class="medical medical_review" href="/d/html/138933.html" rel="external">"Shock in children in resource-limited settings: Initial management", section on 'Severe sepsis and septic shock'</a>.)</p><p class="headingAnchor" id="H21"><span class="h3">Maintenance fluids</span><span class="headingEndMark"> — </span>Maintenance intravenous fluids should include 5 percent dextrose. The rate of fluid administration should be determined by weight [<a href="#rid89">89</a>]; intravenous fluid support should be continued until oral intake is tolerated. (See  <a class="medical medical_review" href="/d/html/6122.html" rel="external">"Maintenance intravenous fluid therapy in children"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Patients weighing &lt;10 kg should receive fluids at a rate of 4 mL/kg/hour.</p><p class="bulletIndent1"><span class="glyph">●</span>Patients weighing 10 to 20 kg should receive 40 mL per hour for the first 10 kg, plus 2 mL/kg/hour for each kg above 10 kg.</p><p class="bulletIndent1"><span class="glyph">●</span>Patients weighing 20 to 80 kg should receive 60 mL per hour for the first 20 kg, 1 mL/kg/hour for every kg above 20 kg; total maintenance fluids are generally capped at approximately 2.5 liters daily.</p><p class="bulletIndent1"><span class="glyph">●</span>Patients weighing more than 80 kg should receive approximately 2.5 liters daily.</p><p></p><p>Most hospitals in endemic areas do not have infusion pumps, and intravenous fluids are usually available in one liter bags only. Therefore, fluid delivery can be difficult to monitor and there is real risk of iatrogenic volume overload. To prevent this problem, interposition of a burette (or "drip chamber") between the patient and the bag may be useful for monitoring intravenous fluid administration. A chamber is filled with a known amount of fluid (generally two hours' worth), labeled with tape, and the drip rate is set. In this way, providers can tell at a glance if the infusion is proceeding as scheduled.</p><p class="headingAnchor" id="H22"><span class="h3">Nutrition</span><span class="headingEndMark"> — </span>Nutritional supplementation should be provided by nasogastric tube for patients with prolonged coma who are unable to eat and drink within 24 to 48 hours. (See  <a class="medical medical_review" href="/d/html/15643.html" rel="external">"Overview of enteral nutrition in infants and children"</a>.)</p><p>In most endemic areas, no commercially prepared enteral products are available; substitutes (such as "eggnog" containing eggs, milk, sugar, and oil) or high-calorie drinks may be used. The volumes calculated for intravenous fluids can be administered via nasogastric tube; the intravenous fluid infusion rate should be decreased accordingly. Most patients are able to eat and drink within five to seven days. (See  <a class="medical medical_review" href="/d/html/6129.html" rel="external">"Oral rehydration therapy"</a>.)</p><p class="headingAnchor" id="H488438328"><span class="h2">Fever</span><span class="headingEndMark"> — </span>High fever (&gt;38.5ºC) is common in the setting of malaria infection and may reflect the host response to endogenous pyrogens released at the time of schizont rupture [<a href="#rid90">90</a>]. The optimal approach to treatment of fever is uncertain, although use of antipyretics in patients with high fever is appropriate given the association between high fever and convulsions [<a href="#rid1">1</a>]. Aggressive temperature control may help reduce long-term neurologic outcomes in pediatric patients with retinopathy-positive cerebral malaria [<a href="#rid58">58</a>].</p><p><a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">Acetaminophen</a> (15 mg/kg every six hours; maximum dose 1000 mg) is a reasonable antipyretic agent; oral therapy can be used for patients able to swallow. Otherwise, suppository formulations are acceptable [<a href="#rid1">1</a>]. If fever persists, <a class="drug drug_general" data-topicid="8547" href="/d/drug information/8547.html" rel="external">ibuprofen</a> (10 mg/kg every six hours; maximum dose 1200 mg per day) can be administered (orally, via nasogastric tube, or IV) alone or on an alternating schedule with paracetamol every three hours.</p><p class="headingAnchor" id="H4176272828"><span class="h2">Concomitant infection</span></p><p class="headingAnchor" id="H1721402882"><span class="h3">HIV coinfection</span><span class="headingEndMark"> — </span>Data on the effect of HIV infection on severe malaria infection are conflicting [<a href="#rid91">91,92</a>]. In one study from Thailand including 74 children with HIV infection with severe malaria, HIV infection was associated with higher parasite burden, more complications, and higher fatality rate [<a href="#rid92">92</a>]. In another study from Malawi including 126 children with HIV infection with severe malaria, HIV infection did not affect parasite density or outcome [<a href="#rid91">91</a>].</p><p>In general, the approach to treatment of malaria is the same in patients with and without HIV infection. Potential drug interactions between antimalarials and antiretroviral drugs should be reviewed carefully [<a href="#rid1">1,93,94</a>].</p><p class="headingAnchor" id="H24"><span class="h3">Bacterial infection</span><span class="headingEndMark"> — </span>Bacterial infection should be suspected in patients with signs or symptoms of sepsis (hypotension, cool extremities, delayed capillary refill, hyperlactatemia). Blood cultures should be obtained and empiric antibiotic therapy with activity against gram-negative bacilli is appropriate for these patients until bacterial infection has been excluded [<a href="#rid1">1,95</a>].</p><p>Concomitant bacteremia may contribute to morbidity and mortality in the setting of severe malaria, particularly in endemic areas. Severe anemia has been implicated as a primary risk factor for invasive bacterial infection [<a href="#rid96">96</a>], most commonly with nontyphoidal <em>Salmonella</em> [<a href="#rid97">97-99</a>]. A study of bacteremia in Kenya identified <em>P. falciparum </em>infection as a major risk factor for bacteremia with multiple organisms [<a href="#rid99">99</a>]. When the community parasite prevalence rate was 29 percent, 62 percent of bacteremia cases were attributable to malaria; the prevalence of bacteremia declined in parallel with the prevalence of malaria infection. A large review of cases of imported malaria noted that community-acquired bacterial coinfection occurred in 8 percent of patients; 2 percent had gram-negative bacteremia [<a href="#rid100">100</a>]. (See  <a class="medical medical_review" href="/d/html/2697.html" rel="external">"Nontyphoidal Salmonella: Gastrointestinal infection and asymptomatic carriage"</a>.)</p><p class="headingAnchor" id="H4290439418"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/113035.html" rel="external">"Society guideline links: Malaria"</a>.)</p><p class="headingAnchor" id="H26"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Severe malaria is acute malaria with major signs of organ dysfunction and/or high level of parasitemia. In endemic areas, young children and pregnant women are at high risk for severe malaria. Older children and adults develop partial immunity after repeated infections and therefore are at relatively low risk for severe disease. Travelers to areas where malaria is endemic generally have no previous exposure to malaria parasites and so are at high risk for severe disease. (See <a class="local">'Definition'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients in rural endemic areas with suspected severe malaria who cannot begin intravenous therapy immediately, we recommend administration of prereferral treatment (<a class="grade" href="https://medilib.ir/uptodate/show/grade_1" rel="external">Grade 1A</a>). (See <a class="local">'Prereferral treatment in rural endemic areas'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Initial treatment of severe malaria consists of parenteral therapy. (See <a class="local">'Initiating therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For areas with no artemisinin resistance, we suggest intravenous <a class="drug drug_general" data-topicid="17088" href="/d/drug information/17088.html" rel="external">artesunate</a> (in areas where intravenous artesunate of reliable quality is readily available) rather than intravenous <a class="drug drug_general" data-topicid="9847" href="/d/drug information/9847.html" rel="external">quinine</a>  (<a class="graphic graphic_table graphicRef79194" href="/d/graphic/79194.html" rel="external">table 5</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_4" rel="external">Grade 2A</a>). This approach is warranted for adults and children (including infants, pregnant women in all trimesters, and lactating women). (See <a class="local">'General approach'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For areas with established artemisinin resistance, such as Southeast Asia, we suggest coadministration of parenteral <a class="drug drug_general" data-topicid="17088" href="/d/drug information/17088.html" rel="external">artesunate</a> and parenteral <a class="drug drug_general" data-topicid="9847" href="/d/drug information/9847.html" rel="external">quinine</a> in full doses (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Areas with artemisinin resistance'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Following administration of parenteral therapy (for at least 24 hours, until oral medication can be tolerated, and parasitemia ≤1 percent in nonimmune patients), an oral regimen should be administered. We suggest treatment with an artemisinin combination therapy (ACT) regimen (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>); if an oral ACT is not available, an alternative regimen may be used. Regimens and dosing are summarized in the table  (<a class="graphic graphic_table graphicRef108036" href="/d/graphic/108036.html" rel="external">table 6</a>). (See <a class="local">'Completing therapy'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For treatment of severe <em>P. falciparum</em> malaria during pregnancy in any trimester, we suggest treatment with intravenous <a class="drug drug_general" data-topicid="17088" href="/d/drug information/17088.html" rel="external">artesunate</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). Among the alternative agents, artemether is preferred over <a class="drug drug_general" data-topicid="9847" href="/d/drug information/9847.html" rel="external">quinine</a>. Following administration of parenteral therapy (for at least 24 hours and until oral medication can be tolerated), an oral regimen should be administered. ACT is preferred; if an oral ACT is not available, an alternative regimen may be used. Regimens and dosing are summarized in the table  (<a class="graphic graphic_table graphicRef52058" href="/d/graphic/52058.html" rel="external">table 7</a>). (See <a class="local">'Pregnancy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Supportive care is critical for patients with severe malaria; death can occur within hours of presentation. Prompt assessment and initiation of antimalarial therapy are essential, followed by concurrent supportive care to manage life-threatening complications of the disease.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pulmonary complications of severe malaria include pulmonary edema, acute respiratory distress syndrome, and lower respiratory tract infection. Management requirements may range from supplementary oxygen to mechanical ventilation. (See <a class="local">'Respiratory status'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Neurologic complications include altered sensorium, seizure, and coma. Clinical evaluation includes full physical examination, calculation of Blantyre Coma Score  (<a class="graphic graphic_table graphicRef74361" href="/d/graphic/74361.html" rel="external">table 2</a>), funduscopic exam, and lumbar puncture. Seizures should be managed as outlined above. (See <a class="local">'Neurologic status'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hematologic complications include severe anemia and coagulopathy. Decisions regarding transfusion should be tailored to individual patient circumstances; in general, we pursue transfusion for children with hemoglobin concentrations &lt;4 g/dL. (See <a class="local">'Transfusion'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hypoglycemia is a common complication of malaria and a marker of severe disease; it should be suspected in any patient who deteriorates suddenly. The threshold for intervention among children &lt;5 years is &lt;3 mmol/L (&lt;54 mg/dL); the threshold for intervention among children ≥5 years and adults is &lt;2.2 mmol/L (&lt;40 mg/dL). Hypoglycemic patients should have intravenous access established promptly, followed by administration of initial bolus of dextrose (0.25 g/kg of body weight), which is usually achieved with 2.5 mL/kg of 10 percent dextrose solution. Blood glucose measurement after 15 minutes should be repeated, with administration of repeat boluses until the patient is normoglycemic. (See <a class="local">'Hypoglycemia'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hypovolemia should be assessed on an individual basis. Adults with malaria appear to be more vulnerable to fluid overload than children; there is a narrow threshold between underhydration (and risk of renal impairment) and overhydration (and risk of pulmonary and cerebral edema). (See <a class="local">'Volume management'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">World Health Organization. Guidelines for malaria, 25 November 2022. https://www.who.int/publications/i/item/guidelines-for-malaria (Accessed on January 23, 2022).</li><li class="breakAll">World Health Organization. World malaria report 2021. https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2021 (Accessed on February 07, 2022).</li><li><a class="nounderline abstract_t">White NJ, Pukrittayakamee S, Hien TT, et al. Malaria. Lancet 2014; 383:723.</a></li><li><a class="nounderline abstract_t">Baird JK. Severe and fatal vivax malaria challenges 'benign tertian malaria' dogma. Ann Trop Paediatr 2009; 29:251.</a></li><li><a class="nounderline abstract_t">Cox-Singh J, Hiu J, Lucas SB, et al. Severe malaria - a case of fatal Plasmodium knowlesi infection with post-mortem findings: a case report. Malar J 2010; 9:10.</a></li><li><a class="nounderline abstract_t">Moxon CA, Zhao L, Li C, et al. Safety of lumbar puncture in comatose children with clinical features of cerebral malaria. Neurology 2016; 87:2355.</a></li><li><a class="nounderline abstract_t">Taylor T, Olola C, Valim C, et al. Standardized data collection for multi-center clinical studies of severe malaria in African children: establishing the SMAC network. Trans R Soc Trop Med Hyg 2006; 100:615.</a></li><li><a class="nounderline abstract_t">Conroy AL, Hawkes MT, Leligdowicz A, et al. Blackwater fever and acute kidney injury in children hospitalized with an acute febrile illness: pathophysiology and prognostic significance. BMC Med 2022; 20:221.</a></li><li><a class="nounderline abstract_t">von Seidlein L, Olaosebikan R, Hendriksen IC, et al. Predicting the clinical outcome of severe falciparum malaria in african children: findings from a large randomized trial. Clin Infect Dis 2012; 54:1080.</a></li><li><a class="nounderline abstract_t">Gomes MF, Faiz MA, Gyapong JO, et al. Pre-referral rectal artesunate to prevent death and disability in severe malaria: a placebo-controlled trial. Lancet 2009; 373:557.</a></li><li><a class="nounderline abstract_t">Okebe J, Eisenhut M. Pre-referral rectal artesunate for severe malaria. Cochrane Database Syst Rev 2014; :CD009964.</a></li><li><a class="nounderline abstract_t">Dondorp AM, Fanello CI, Hendriksen IC, et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet 2010; 376:1647.</a></li><li><a class="nounderline abstract_t">Sinclair D, Donegan S, Isba R, Lalloo DG. Artesunate versus quinine for treating severe malaria. Cochrane Database Syst Rev 2012; :CD005967.</a></li><li><a class="nounderline abstract_t">Kurth F, Develoux M, Mechain M, et al. Intravenous Artesunate Reduces Parasite Clearance Time, Duration of Intensive Care, and Hospital Treatment in Patients With Severe Malaria in Europe: The TropNet Severe Malaria Study. Clin Infect Dis 2015; 61:1441.</a></li><li><a class="nounderline abstract_t">Esu EB, Effa EE, Opie ON, Meremikwu MM. Artemether for severe malaria. Cochrane Database Syst Rev 2019; 6:CD010678.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Treatment of Malaria: Guidelines for Clinicians (United States) - Treatment of Severe Malaria. https://www.cdc.gov/malaria/diagnosis_treatment/clinicians1.html#severe (Accessed on October 04, 2022).</li><li class="breakAll">United States Centers for Disease Control and Prevention. Guidelines for Treatment of Malaria in the United States: https://www.cdc.gov/malaria/resources/pdf/Malaria_Treatment_Table.pdf (Accessed on November 09, 2022).</li><li><a class="nounderline abstract_t">Botta A, Comelli A, Vellere I, et al. Artesunate monotherapy versus artesunate plus quinine combination therapy for treatment of imported severe malaria: a TropNet retrospective cohort study. Infection 2022; 50:949.</a></li><li><a class="nounderline abstract_t">Phyo AP, Win KK, Thu AM, et al. Poor response to artesunate treatment in two patients with severe malaria on the Thai-Myanmar border. Malar J 2018; 17:30.</a></li><li><a class="nounderline abstract_t">Dondorp A, Nosten F, Stepniewska K, et al. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet 2005; 366:717.</a></li><li><a class="nounderline abstract_t">Rosenthal PJ. Artesunate for the treatment of severe falciparum malaria. N Engl J Med 2008; 358:1829.</a></li><li><a class="nounderline abstract_t">ter Kuile F, White NJ, Holloway P, et al. Plasmodium falciparum: in vitro studies of the pharmacodynamic properties of drugs used for the treatment of severe malaria. Exp Parasitol 1993; 76:85.</a></li><li><a class="nounderline abstract_t">El Ket N, Kendjo E, Thellier M, et al. Propensity Score Analysis of Artesunate Versus Quinine for Severe Imported Plasmodium falciparum Malaria in France. Clin Infect Dis 2020; 70:280.</a></li><li><a class="nounderline abstract_t">Twomey PS, Smith BL, McDermott C, et al. Intravenous Artesunate for the Treatment of Severe and Complicated Malaria in the United States: Clinical Use Under an Investigational New Drug Protocol. Ann Intern Med 2015; 163:498.</a></li><li><a class="nounderline abstract_t">Rolling T, Schmiedel S, Wichmann D, et al. Post-treatment haemolysis in severe imported malaria after intravenous artesunate: case report of three patients with hyperparasitaemia. Malar J 2012; 11:169.</a></li><li><a class="nounderline abstract_t">Kreeftmeijer-Vegter AR, van Genderen PJ, Visser LG, et al. Treatment outcome of intravenous artesunate in patients with severe malaria in the Netherlands and Belgium. Malar J 2012; 11:102.</a></li><li><a class="nounderline abstract_t">Zoller T, Junghanss T, Kapaun A, et al. Intravenous artesunate for severe malaria in travelers, Europe. Emerg Infect Dis 2011; 17:771.</a></li><li><a class="nounderline abstract_t">Caramello P, Balbiano R, De Blasi T, et al. Severe malaria, artesunate and haemolysis. J Antimicrob Chemother 2012; 67:2053.</a></li><li><a class="nounderline abstract_t">Kano S. Artemisinin-based combination therapies and their introduction in Japan. J Infect Chemother 2010; 16:375.</a></li><li><a class="nounderline abstract_t">Rolling T, Agbenyega T, Issifou S, et al. Delayed hemolysis after treatment with parenteral artesunate in African children with severe malaria--a double-center prospective study. J Infect Dis 2014; 209:1921.</a></li><li><a class="nounderline abstract_t">Paczkowski MM, Landman KL, Arguin PM, Centers for Disease Control and Prevention (CDC). Update on cases of delayed hemolysis after parenteral artesunate therapy for malaria - United States, 2008 and 2013. MMWR Morb Mortal Wkly Rep 2014; 63:753.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Published reports of delayed hemolytic anemia after treatment with artesunate for severe malaria--worldwide, 2010-2012. MMWR Morb Mortal Wkly Rep 2013; 62:5.</a></li><li><a class="nounderline abstract_t">Jauréguiberry S, Ndour PA, Roussel C, et al. Postartesunate delayed hemolysis is a predictable event related to the lifesaving effect of artemisinins. Blood 2014; 124:167.</a></li><li><a class="nounderline abstract_t">Gómez-Junyent J, Ruiz-Panales P, Calvo-Cano A, et al. Delayed haemolysis after artesunate therapy in a cohort of patients with severe imported malaria due to Plasmodium falciparum. Enferm Infecc Microbiol Clin 2017; 35:516.</a></li><li><a class="nounderline abstract_t">Ndour PA, Larréché S, Mouri O, et al. Measuring the Plasmodium falciparum HRP2 protein in blood from artesunate-treated malaria patients predicts post-artesunate delayed hemolysis. Sci Transl Med 2017; 9.</a></li><li><a class="nounderline abstract_t">Angus BJ, Chotivanich K, Udomsangpetch R, White NJ. In vivo removal of malaria parasites from red blood cells without their destruction in acute falciparum malaria. Blood 1997; 90:2037.</a></li><li><a class="nounderline abstract_t">Chotivanich K, Udomsangpetch R, Dondorp A, et al. The mechanisms of parasite clearance after antimalarial treatment of Plasmodium falciparum malaria. J Infect Dis 2000; 182:629.</a></li><li><a class="nounderline abstract_t">Nontprasert A, Pukrittayakamee S, Nosten-Bertrand M, et al. Studies of the neurotoxicity of oral artemisinin derivatives in mice. Am J Trop Med Hyg 2000; 62:409.</a></li><li><a class="nounderline abstract_t">White NJ. Cardiotoxicity of antimalarial drugs. Lancet Infect Dis 2007; 7:549.</a></li><li><a class="nounderline abstract_t">White NJ. The treatment of malaria. N Engl J Med 1996; 335:800.</a></li><li><a class="nounderline abstract_t">Griffith KS, Lewis LS, Mali S, Parise ME. Treatment of malaria in the United States: a systematic review. JAMA 2007; 297:2264.</a></li><li><a class="nounderline abstract_t">Bouchaud O, Mühlberger N, Parola P, et al. Therapy of uncomplicated falciparum malaria in Europe: MALTHER - a prospective observational multicentre study. Malar J 2012; 11:212.</a></li><li><a class="nounderline abstract_t">Das D, Price RN, Bethell D, et al. Early parasitological response following artemisinin-containing regimens: a critical review of the literature. Malar J 2013; 12:125.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Counterfeit and Substandard Antimalarial Drugs. www.cdc.gov/malaria/malaria_worldwide/reduction/counterfeit.html (Accessed on February 24, 2020).</li><li><a class="nounderline abstract_t">Kwambai TK, Dhabangi A, Idro R, et al. Malaria Chemoprevention in the Postdischarge Management of Severe Anemia. N Engl J Med 2020; 383:2242.</a></li><li><a class="nounderline abstract_t">Bassat Q, Machevo S, O'Callaghan-Gordo C, et al. Distinguishing malaria from severe pneumonia among hospitalized children who fulfilled integrated management of childhood illness criteria for both diseases: a hospital-based study in Mozambique. Am J Trop Med Hyg 2011; 85:626.</a></li><li><a class="nounderline abstract_t">Marsh K, Forster D, Waruiru C, et al. Indicators of life-threatening malaria in African children. N Engl J Med 1995; 332:1399.</a></li><li><a class="nounderline abstract_t">Hendriksen IC, Mtove G, Pedro AJ, et al. Evaluation of a PfHRP2 and a pLDH-based rapid diagnostic test for the diagnosis of severe malaria in 2 populations of African children. Clin Infect Dis 2011; 52:1100.</a></li><li><a class="nounderline abstract_t">Taylor TE, Fu WJ, Carr RA, et al. Differentiating the pathologies of cerebral malaria by postmortem parasite counts. Nat Med 2004; 10:143.</a></li><li><a class="nounderline abstract_t">Lewallen S, White VA, Whitten RO, et al. Clinical-histopathological correlation of the abnormal retinal vessels in cerebral malaria. Arch Ophthalmol 2000; 118:924.</a></li><li><a class="nounderline abstract_t">Beare NA, Taylor TE, Harding SP, et al. Malarial retinopathy: a newly established diagnostic sign in severe malaria. Am J Trop Med Hyg 2006; 75:790.</a></li><li><a class="nounderline abstract_t">Beare NA, Harding SP, Taylor TE, et al. Perfusion abnormalities in children with cerebral malaria and malarial retinopathy. J Infect Dis 2009; 199:263.</a></li><li><a class="nounderline abstract_t">Barrera V, Hiscott PS, Craig AG, et al. Severity of retinopathy parallels the degree of parasite sequestration in the eyes and brains of malawian children with fatal cerebral malaria. J Infect Dis 2015; 211:1977.</a></li><li><a class="nounderline abstract_t">Govindasamy G, Barber BE, Ghani SA, et al. Retinal Changes in Uncomplicated and Severe Plasmodium knowlesi Malaria. J Infect Dis 2016; 213:1476.</a></li><li><a class="nounderline abstract_t">Seydel KB, Kampondeni SD, Valim C, et al. Brain swelling and death in children with cerebral malaria. N Engl J Med 2015; 372:1126.</a></li><li><a class="nounderline abstract_t">Newton CR, Chokwe T, Schellenberg JA, et al. Coma scales for children with severe falciparum malaria. Trans R Soc Trop Med Hyg 1997; 91:161.</a></li><li><a class="nounderline abstract_t">Molyneux ME, Taylor TE, Wirima JJ, Borgstein A. Clinical features and prognostic indicators in paediatric cerebral malaria: a study of 131 comatose Malawian children. Q J Med 1989; 71:441.</a></li><li><a class="nounderline abstract_t">Birbeck GL, Molyneux ME, Kaplan PW, et al. Blantyre Malaria Project Epilepsy Study (BMPES) of neurological outcomes in retinopathy-positive paediatric cerebral malaria survivors: a prospective cohort study. Lancet Neurol 2010; 9:1173.</a></li><li><a class="nounderline abstract_t">Seydel KB, Fox LL, Glover SJ, et al. Plasma concentrations of parasite histidine-rich protein 2 distinguish between retinopathy-positive and retinopathy-negative cerebral malaria in Malawian children. J Infect Dis 2012; 206:309.</a></li><li><a class="nounderline abstract_t">Fox LL, Taylor TE, Pensulo P, et al. Histidine-rich protein 2 plasma levels predict progression to cerebral malaria in Malawian children with Plasmodium falciparum infection. J Infect Dis 2013; 208:500.</a></li><li><a class="nounderline abstract_t">Kariuki SM, Gitau E, Gwer S, et al. Value of Plasmodium falciparum histidine-rich protein 2 level and malaria retinopathy in distinguishing cerebral malaria from other acute encephalopathies in Kenyan children. J Infect Dis 2014; 209:600.</a></li><li><a class="nounderline abstract_t">Jakka SR, Veena S, Atmakuri RM, Eisenhut M. Characteristic abnormalities in cerebrospinal fluid biochemistry in children with cerebral malaria compared to viral encephalitis. Cerebrospinal Fluid Res 2006; 3:8.</a></li><li><a class="nounderline abstract_t">Crawley J, Smith S, Muthinji P, et al. Electroencephalographic and clinical features of cerebral malaria. Arch Dis Child 2001; 84:247.</a></li><li><a class="nounderline abstract_t">Crawley J, Waruiru C, Mithwani S, et al. Effect of phenobarbital on seizure frequency and mortality in childhood cerebral malaria: a randomised, controlled intervention study. Lancet 2000; 355:701.</a></li><li><a class="nounderline abstract_t">Bangirana P, Opoka RO, Boivin MJ, et al. Severe malarial anemia is associated with long-term neurocognitive impairment. Clin Infect Dis 2014; 59:336.</a></li><li><a class="nounderline abstract_t">Ackerman H, Ayestaran A, Olola CHO, et al. The effect of blood transfusion on outcomes among African children admitted to hospital with Plasmodium falciparum malaria: a prospective, multicentre observational study. Lancet Haematol 2020; 7:e789.</a></li><li><a class="nounderline abstract_t">Maitland K, Kiguli S, Olupot-Olupot P, et al. Transfusion management of severe anaemia in African children: a consensus algorithm. Br J Haematol 2021; 193:1247.</a></li><li><a class="nounderline abstract_t">Maitland K, Kiguli S, Olupot-Olupot P, et al. Immediate Transfusion in African Children with Uncomplicated Severe Anemia. N Engl J Med 2019; 381:407.</a></li><li><a class="nounderline abstract_t">Maitland K, Olupot-Olupot P, Kiguli S, et al. Transfusion Volume for Children with Severe Anemia in Africa. N Engl J Med 2019; 381:420.</a></li><li><a class="nounderline abstract_t">Riddle MS, Jackson JL, Sanders JW, Blazes DL. Exchange transfusion as an adjunct therapy in severe Plasmodium falciparum malaria: a meta-analysis. Clin Infect Dis 2002; 34:1192.</a></li><li><a class="nounderline abstract_t">Tan KR, Wiegand RE, Arguin PM. Exchange transfusion for severe malaria: evidence base and literature review. Clin Infect Dis 2013; 57:923.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Exchange Transfusion for Treatment of Severe Malaria No Longer Recommended. http://www.cdc.gov/malaria/new_info/2013/exchange_transfusion.html (Accessed on January 31, 2014).</li><li><a class="nounderline abstract_t">Zucker JR, Campbell CC. Malaria. Principles of prevention and treatment. Infect Dis Clin North Am 1993; 7:547.</a></li><li><a class="nounderline abstract_t">Connelly-Smith L, Alquist CR, Aqui NA, et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue. J Clin Apher 2023; 38:77.</a></li><li><a class="nounderline abstract_t">Plewes K, Kingston HWF, Ghose A, et al. Acetaminophen as a Renoprotective Adjunctive Treatment in Patients With Severe and Moderately Severe Falciparum Malaria: A Randomized, Controlled, Open-Label Trial. Clin Infect Dis 2018; 67:991.</a></li><li><a class="nounderline abstract_t">White NJ, Miller KD, Marsh K, et al. Hypoglycaemia in African children with severe malaria. Lancet 1987; 1:708.</a></li><li><a class="nounderline abstract_t">Taylor TE, Molyneux ME, Wirima JJ, et al. Blood glucose levels in Malawian children before and during the administration of intravenous quinine for severe falciparum malaria. N Engl J Med 1988; 319:1040.</a></li><li><a class="nounderline abstract_t">Willcox ML, Forster M, Dicko MI, et al. Blood glucose and prognosis in children with presumed severe malaria: is there a threshold for 'hypoglycaemia'? Trop Med Int Health 2010; 15:232.</a></li><li><a class="nounderline abstract_t">White NJ, Warrell DA, Chanthavanich P, et al. Severe hypoglycemia and hyperinsulinemia in falciparum malaria. N Engl J Med 1983; 309:61.</a></li><li><a class="nounderline abstract_t">Limburg PJ, Katz H, Grant CS, Service FJ. Quinine-induced hypoglycemia. Ann Intern Med 1993; 119:218.</a></li><li><a class="nounderline abstract_t">Maitland K, Levin M, English M, et al. Severe P. falciparum malaria in Kenyan children: evidence for hypovolaemia. QJM 2003; 96:427.</a></li><li><a class="nounderline abstract_t">Planche T, Onanga M, Schwenk A, et al. Assessment of volume depletion in children with malaria. PLoS Med 2004; 1:e18.</a></li><li><a class="nounderline abstract_t">Hanson JP, Lam SW, Mohanty S, et al. Fluid resuscitation of adults with severe falciparum malaria: effects on Acid-base status, renal function, and extravascular lung water. Crit Care Med 2013; 41:972.</a></li><li><a class="nounderline abstract_t">Maitland K, Kiguli S, Opoka RO, et al. Mortality after fluid bolus in African children with severe infection. N Engl J Med 2011; 364:2483.</a></li><li><a class="nounderline abstract_t">Ishioka H, Plewes K, Pattnaik R, et al. Associations Between Restrictive Fluid Management and Renal Function and Tissue Perfusion in Adults With Severe Falciparum Malaria: A Prospective Observational Study. J Infect Dis 2020; 221:285.</a></li><li><a class="nounderline abstract_t">Brown H, Hien TT, Day N, et al. Evidence of blood-brain barrier dysfunction in human cerebral malaria. Neuropathol Appl Neurobiol 1999; 25:331.</a></li><li><a class="nounderline abstract_t">Maitland K, Pamba A, English M, et al. Randomized trial of volume expansion with albumin or saline in children with severe malaria: preliminary evidence of albumin benefit. Clin Infect Dis 2005; 40:538.</a></li><li><a class="nounderline abstract_t">Phu NH, Hien TT, Mai NT, et al. Hemofiltration and peritoneal dialysis in infection-associated acute renal failure in Vietnam. N Engl J Med 2002; 347:895.</a></li><li><a class="nounderline abstract_t">Duke T, Molyneux EM. Intravenous fluids for seriously ill children: time to reconsider. Lancet 2003; 362:1320.</a></li><li><a class="nounderline abstract_t">Hensmann M, Kwiatkowski D. Cellular basis of early cytokine response to Plasmodium falciparum. Infect Immun 2001; 69:2364.</a></li><li><a class="nounderline abstract_t">Mbale EW, Moxon CA, Mukaka M, et al. HIV coinfection influences the inflammatory response but not the outcome of cerebral malaria in Malawian children. J Infect 2016; 73:189.</a></li><li><a class="nounderline abstract_t">Hendriksen IC, Ferro J, Montoya P, et al. Diagnosis, clinical presentation, and in-hospital mortality of severe malaria in HIV-coinfected children and adults in Mozambique. Clin Infect Dis 2012; 55:1144.</a></li><li><a class="nounderline abstract_t">Khoo S, Back D, Winstanley P. The potential for interactions between antimalarial and antiretroviral drugs. AIDS 2005; 19:995.</a></li><li><a class="nounderline abstract_t">Hoglund RM, Byakika-Kibwika P, Lamorde M, et al. Artemether-lumefantrine co-administration with antiretrovirals: population pharmacokinetics and dosing implications. Br J Clin Pharmacol 2015; 79:636.</a></li><li><a class="nounderline abstract_t">Nyein PP, Aung NM, Kyi TT, et al. High Frequency of Clinically Significant Bacteremia in Adults Hospitalized With Falciparum Malaria. Open Forum Infect Dis 2016; 3:ofw028.</a></li><li><a class="nounderline abstract_t">Church J, Maitland K. Invasive bacterial co-infection in African children with Plasmodium falciparum malaria: a systematic review. BMC Med 2014; 12:31.</a></li><li><a class="nounderline abstract_t">Berkley J, Mwarumba S, Bramham K, et al. Bacteraemia complicating severe malaria in children. Trans R Soc Trop Med Hyg 1999; 93:283.</a></li><li><a class="nounderline abstract_t">Bronzan RN, Taylor TE, Mwenechanya J, et al. Bacteremia in Malawian children with severe malaria: prevalence, etiology, HIV coinfection, and outcome. J Infect Dis 2007; 195:895.</a></li><li><a class="nounderline abstract_t">Scott JA, Berkley JA, Mwangi I, et al. Relation between falciparum malaria and bacteraemia in Kenyan children: a population-based, case-control study and a longitudinal study. Lancet 2011; 378:1316.</a></li><li><a class="nounderline abstract_t">Marks M, Armstrong M, Walker D, Doherty T. Imported falciparum malaria among adults requiring intensive care: analysis of the literature. Malar J 2014; 13:79.</a></li></ol></div><div id="topicVersionRevision">Topic 5667 Version 85.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://www.who.int/publications/i/item/guidelines-for-malaria" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : World Health Organization. Guidelines for malaria, 25 November 2022. https://www.who.int/publications/i/item/guidelines-for-malaria (Accessed on January 23, 2022).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2021" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : World Health Organization. World malaria report 2021. https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2021 (Accessed on February 07, 2022).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23953767" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19941746" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Severe and fatal vivax malaria challenges 'benign tertian malaria' dogma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20064229" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Severe malaria - a case of fatal Plasmodium knowlesi infection with post-mortem findings: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27794112" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Safety of lumbar puncture in comatose children with clinical features of cerebral malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16551469" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Standardized data collection for multi-center clinical studies of severe malaria in African children: establishing the SMAC network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35773743" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Blackwater fever and acute kidney injury in children hospitalized with an acute febrile illness: pathophysiology and prognostic significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22412067" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Predicting the clinical outcome of severe falciparum malaria in african children: findings from a large randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19059639" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Pre-referral rectal artesunate to prevent death and disability in severe malaria: a placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24869943" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Pre-referral rectal artesunate for severe malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21062666" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22696354" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Artesunate versus quinine for treating severe malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26187021" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Intravenous Artesunate Reduces Parasite Clearance Time, Duration of Intensive Care, and Hospital Treatment in Patients With Severe Malaria in Europe: The TropNet Severe Malaria Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31210357" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Artemether for severe malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31210357" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Artemether for severe malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31210357" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Artemether for severe malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35220555" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Artesunate monotherapy versus artesunate plus quinine combination therapy for treatment of imported severe malaria: a TropNet retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29334942" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Poor response to artesunate treatment in two patients with severe malaria on the Thai-Myanmar border.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16125588" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18434652" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Artesunate for the treatment of severe falciparum malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8467901" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Plasmodium falciparum: in vitro studies of the pharmacodynamic properties of drugs used for the treatment of severe malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30874798" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Propensity Score Analysis of Artesunate Versus Quinine for Severe Imported Plasmodium falciparum Malaria in France.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26301474" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Intravenous Artesunate for the Treatment of Severe and Complicated Malaria in the United States: Clinical Use Under an Investigational New Drug Protocol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22594446" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Post-treatment haemolysis in severe imported malaria after intravenous artesunate: case report of three patients with hyperparasitaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22462806" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Treatment outcome of intravenous artesunate in patients with severe malaria in the Netherlands and Belgium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21529383" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Intravenous artesunate for severe malaria in travelers, Europe.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22523307" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Severe malaria, artesunate and haemolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20535521" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Artemisinin-based combination therapies and their introduction in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24376273" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Delayed hemolysis after treatment with parenteral artesunate in African children with severe malaria--a double-center prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25166926" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Update on cases of delayed hemolysis after parenteral artesunate therapy for malaria - United States, 2008 and 2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23302816" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Published reports of delayed hemolytic anemia after treatment with artesunate for severe malaria--worldwide, 2010-2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24859359" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Postartesunate delayed hemolysis is a predictable event related to the lifesaving effect of artemisinins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26708338" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Delayed haemolysis after artesunate therapy in a cohort of patients with severe imported malaria due to Plasmodium falciparum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28679662" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Measuring the Plasmodium falciparum HRP2 protein in blood from artesunate-treated malaria patients predicts post-artesunate delayed hemolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9292540" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : In vivo removal of malaria parasites from red blood cells without their destruction in acute falciparum malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10915102" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The mechanisms of parasite clearance after antimalarial treatment of Plasmodium falciparum malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11037787" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Studies of the neurotoxicity of oral artemisinin derivatives in mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17646028" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Cardiotoxicity of antimalarial drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8703186" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The treatment of malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17519416" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Treatment of malaria in the United States: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22720832" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Therapy of uncomplicated falciparum malaria in Europe: MALTHER - a prospective observational multicentre study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23602021" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Early parasitological response following artemisinin-containing regimens: a critical review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23602021" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Early parasitological response following artemisinin-containing regimens: a critical review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33264546" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Malaria Chemoprevention in the Postdischarge Management of Severe Anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21976562" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Distinguishing malaria from severe pneumonia among hospitalized children who fulfilled integrated management of childhood illness criteria for both diseases: a hospital-based study in Mozambique.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7723795" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Indicators of life-threatening malaria in African children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21467015" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Evaluation of a PfHRP2 and a pLDH-based rapid diagnostic test for the diagnosis of severe malaria in 2 populations of African children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14745442" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Differentiating the pathologies of cerebral malaria by postmortem parasite counts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10900105" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Clinical-histopathological correlation of the abnormal retinal vessels in cerebral malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17123967" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Malarial retinopathy: a newly established diagnostic sign in severe malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18999956" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Perfusion abnormalities in children with cerebral malaria and malarial retinopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25351204" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Severity of retinopathy parallels the degree of parasite sequestration in the eyes and brains of malawian children with fatal cerebral malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26671886" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Retinal Changes in Uncomplicated and Severe Plasmodium knowlesi Malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25785970" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Brain swelling and death in children with cerebral malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9196757" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Coma scales for children with severe falciparum malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2690177" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Clinical features and prognostic indicators in paediatric cerebral malaria: a study of 131 comatose Malawian children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21056005" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Blantyre Malaria Project Epilepsy Study (BMPES) of neurological outcomes in retinopathy-positive paediatric cerebral malaria survivors: a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22634877" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Plasma concentrations of parasite histidine-rich protein 2 distinguish between retinopathy-positive and retinopathy-negative cerebral malaria in Malawian children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23630364" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Histidine-rich protein 2 plasma levels predict progression to cerebral malaria in Malawian children with Plasmodium falciparum infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24041795" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Value of Plasmodium falciparum histidine-rich protein 2 level and malaria retinopathy in distinguishing cerebral malaria from other acute encephalopathies in Kenyan children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16764711" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Characteristic abnormalities in cerebrospinal fluid biochemistry in children with cerebral malaria compared to viral encephalitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11207176" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Electroencephalographic and clinical features of cerebral malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10703801" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Effect of phenobarbital on seizure frequency and mortality in childhood cerebral malaria: a randomised, controlled intervention study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24771329" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Severe malarial anemia is associated with long-term neurocognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33091354" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : The effect of blood transfusion on outcomes among African children admitted to hospital with Plasmodium falciparum malaria: a prospective, multicentre observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33955552" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Transfusion management of severe anaemia in African children: a consensus algorithm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31365799" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Immediate Transfusion in African Children with Uncomplicated Severe Anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31365800" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Transfusion Volume for Children with Severe Anemia in Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11941545" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Exchange transfusion as an adjunct therapy in severe Plasmodium falciparum malaria: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23800940" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Exchange transfusion for severe malaria: evidence base and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23800940" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Exchange transfusion for severe malaria: evidence base and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8254159" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Malaria. Principles of prevention and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37017433" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29538635" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Acetaminophen as a Renoprotective Adjunctive Treatment in Patients With Severe and Moderately Severe Falciparum Malaria: A Randomized, Controlled, Open-Label Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2882130" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Hypoglycaemia in African children with severe malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3050516" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Blood glucose levels in Malawian children before and during the administration of intravenous quinine for severe falciparum malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19961563" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Blood glucose and prognosis in children with presumed severe malaria: is there a threshold for 'hypoglycaemia'?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6343877" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Severe hypoglycemia and hyperinsulinemia in falciparum malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8323090" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Quinine-induced hypoglycemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12788961" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Severe P. falciparum malaria in Kenyan children: evidence for hypovolaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15526044" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Assessment of volume depletion in children with malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23324951" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Fluid resuscitation of adults with severe falciparum malaria: effects on Acid-base status, renal function, and extravascular lung water.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21615299" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Mortality after fluid bolus in African children with severe infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31504666" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Associations Between Restrictive Fluid Management and Renal Function and Tissue Perfusion in Adults With Severe Falciparum Malaria: A Prospective Observational Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10476050" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Evidence of blood-brain barrier dysfunction in human cerebral malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15712076" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Randomized trial of volume expansion with albumin or saline in children with severe malaria: preliminary evidence of albumin benefit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12239258" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Hemofiltration and peritoneal dialysis in infection-associated acute renal failure in Vietnam.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14575980" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Intravenous fluids for seriously ill children: time to reconsider.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11254594" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Cellular basis of early cytokine response to Plasmodium falciparum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27311750" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : HIV coinfection influences the inflammatory response but not the outcome of cerebral malaria in Malawian children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22752514" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Diagnosis, clinical presentation, and in-hospital mortality of severe malaria in HIV-coinfected children and adults in Mozambique.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15958830" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : The potential for interactions between antimalarial and antiretroviral drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25297720" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Artemether-lumefantrine co-administration with antiretrovirals: population pharmacokinetics and dosing implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26989752" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : High Frequency of Clinically Significant Bacteremia in Adults Hospitalized With Falciparum Malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24548672" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Invasive bacterial co-infection in African children with Plasmodium falciparum malaria: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10492760" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Bacteraemia complicating severe malaria in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17299721" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Bacteremia in Malawian children with severe malaria: prevalence, etiology, HIV coinfection, and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21903251" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Relation between falciparum malaria and bacteraemia in Kenyan children: a population-based, case-control study and a longitudinal study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24602328" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Imported falciparum malaria among adults requiring intensive care: analysis of the literature.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
